Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The C11orf54-MED17 readthrough (ENSG00000284057) refers to a predicted gene fusion from readthrough transcription of C11orf54 and MED17 on chromosome 11. C11orf54 (also known as PTD012) is a zinc-binding ester hydrolase, recently identified as β-keto-L-gulonate decarboxylase in human pentose metabolism. C11orf54 is implicated in DNA damage response, DNA repair, cell proliferation regulation, and autophagy modulating pathways, and has been studied as a biomarker in renal and prostate cancers. MED17 encodes a core subunit of the Mediator complex, essential for bridging transcription factors and RNA polymerase II in gene regulation. There is currently no direct experimental evidence for a functional C11orf54-MED17 fusion protein, and its biological significance is unknown; the entry appears to arise from gene annotation or computational prediction rather than proven protein existence or therapeutic relevance.
Not applicable for the fusion; not a known drug target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel protein, C11orf54-MED17 readthrough (C11orf54-MED17 readthrough).